RU2010144744A - Композиции и способы иммунотерапии - Google Patents

Композиции и способы иммунотерапии Download PDF

Info

Publication number
RU2010144744A
RU2010144744A RU2010144744/15A RU2010144744A RU2010144744A RU 2010144744 A RU2010144744 A RU 2010144744A RU 2010144744/15 A RU2010144744/15 A RU 2010144744/15A RU 2010144744 A RU2010144744 A RU 2010144744A RU 2010144744 A RU2010144744 A RU 2010144744A
Authority
RU
Russia
Prior art keywords
specified
benzaldehyde
derivative
formula
effective
Prior art date
Application number
RU2010144744/15A
Other languages
English (en)
Russian (ru)
Inventor
Джо Эрнест БРАУН (US)
Джо Эрнест БРАУН
Original Assignee
Когнейт 3, Ллс (Us)
Когнейт 3, Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Когнейт 3, Ллс (Us), Когнейт 3, Ллс filed Critical Когнейт 3, Ллс (Us)
Publication of RU2010144744A publication Critical patent/RU2010144744A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
RU2010144744/15A 2008-04-03 2009-04-03 Композиции и способы иммунотерапии RU2010144744A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4221008P 2008-04-03 2008-04-03
US61/042,210 2008-04-03

Publications (1)

Publication Number Publication Date
RU2010144744A true RU2010144744A (ru) 2012-05-10

Family

ID=41267359

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010144744/15A RU2010144744A (ru) 2008-04-03 2009-04-03 Композиции и способы иммунотерапии

Country Status (12)

Country Link
US (5) US20090281047A1 (enExample)
EP (1) EP2271350A4 (enExample)
JP (1) JP2011516478A (enExample)
CN (1) CN102046180A (enExample)
AU (1) AU2009251848A1 (enExample)
CA (1) CA2757437A1 (enExample)
IL (1) IL208445A0 (enExample)
MX (1) MX339451B (enExample)
NZ (1) NZ588668A (enExample)
RU (1) RU2010144744A (enExample)
WO (1) WO2009145841A1 (enExample)
ZA (1) ZA201007830B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
AU2009335943A1 (en) 2008-12-19 2013-10-24 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
PL2453747T3 (pl) 2009-07-13 2018-02-28 Medicis Pharmaceutical Corporation Preparaty imikwimodu o niższej mocy dawki i krótkie schematy dawkowania do leczenia brodawek narządów płciowych i okolic odbytu
KR101850566B1 (ko) * 2010-06-07 2018-04-19 아브락시스 바이오사이언스, 엘엘씨 증식성 질환의 치료를 위한 조합 치료 방법
US20130171279A1 (en) * 2012-01-04 2013-07-04 Physicianrx, Llc Composition for Reducing Side- and After-Effects of Cancer Treatment
CN103156951A (zh) * 2013-04-11 2013-06-19 太仓市胜舟生物技术有限公司 一种治疗b细胞淋巴瘤的组合药物
ES2886019T3 (es) * 2013-12-20 2021-12-16 Campillo Ramiro Moises Vergara Combinación de piridoxina, ácido fólico e iones magnesio para el tratamiento del cáncer
SG11201805375PA (en) * 2016-02-04 2018-07-30 Stem Cell Theranostics Inc Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
EP3493815B1 (en) * 2016-08-03 2022-02-16 Zhuhai Beihai Biotech Co., Ltd. Formulations of fosaprepitant and aprepitant
CA3108483A1 (en) * 2017-08-07 2019-02-14 Cognate 3 Llc Compositions and methods for inducing apoptosis in anaerobic cells and related clinical methods for treating cancer and pathogenic infections
IL307204A (en) * 2021-03-25 2023-11-01 Shmuel Robinov Benzaldehyde extracted from rosales as foodstuff preservative, animal-feed additive, and for treatment of the covid-19 virus
JP7018531B1 (ja) 2021-04-30 2022-02-10 潤 齋藤 Ａｘｌ阻害剤
WO2023161862A2 (en) * 2022-02-24 2023-08-31 Robinov Shmuel Methods of use of benzaldehyde compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882314A (en) * 1985-12-02 1989-11-21 Rikagaku Kenkyusho A composition and method of treating selected malignant conditions
US6407071B1 (en) * 1998-06-04 2002-06-18 Co-Enzyme Technology Ltd. Method and composition for treating malignant cells
NO309305B1 (no) * 1999-02-19 2001-01-15 Norsk Hydro As Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater

Also Published As

Publication number Publication date
MX339451B (es) 2016-05-27
US20110311476A1 (en) 2011-12-22
CA2757437A1 (en) 2009-12-03
EP2271350A4 (en) 2011-05-18
CN102046180A (zh) 2011-05-04
US20120251490A1 (en) 2012-10-04
JP2011516478A (ja) 2011-05-26
US20110311477A1 (en) 2011-12-22
MX2010010866A (es) 2011-02-24
WO2009145841A1 (en) 2009-12-03
EP2271350A1 (en) 2011-01-12
US20090281047A1 (en) 2009-11-12
US20110311478A1 (en) 2011-12-22
NZ588668A (en) 2013-01-25
AU2009251848A1 (en) 2009-12-03
ZA201007830B (en) 2011-07-27
IL208445A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
RU2010144744A (ru) Композиции и способы иммунотерапии
JP2011516478A5 (enExample)
CN102421429B (zh) 癌症治疗用选择性ep4受体拮抗物质
RU2498804C2 (ru) Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
US10292962B2 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
US9211291B2 (en) Treatment regimen utilizing neratinib for breast cancer
JP2013531068A (ja) ４−ヨード−３−ニトロベンズアミドを抗腫瘍剤と組み合わせて用いる乳癌の治療方法
KR20130015669A (ko) 암의 재발 또는 전이의 억제용 약제학적 조성물
US20240325397A1 (en) Use of combination therapy for treating cancer
RU2017137008A (ru) Антагонисты толл-подобного рецептора 4 и применение при аутоиммунных заболеваниях печени
US20200237779A1 (en) Combination therapy with a bet inhibitor and a bcl-2 inhibitor
JP2016501884A5 (enExample)
TW202133848A (zh) 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物
JP5570429B2 (ja) デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法
TW201244732A (en) Ezatiostat for treating multiple myeloma
HK1167090B (en) Selective ep4 receptor agonistic substance for treatment of cancer
HK1225604A (en) Selective ep4 receptor agonistic substance for treatment of cancer
HK1225604A1 (en) Selective ep4 receptor agonistic substance for treatment of cancer
US20120245117A1 (en) Methods of treating squamous cell lung cancer with 4-iodo-3-nitrobenzamide in combination with gemcitabine and carboplatin
HK1225604B (zh) 癌症治疗用选择性ep4受体拮抗物质
HK1167090A (en) Selective ep4 receptor agonistic substance for treatment of cancer
HK1223027B (en) Treatment regimen utilizing neratinib for breast cancer

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20140626